| [1] |
Siegel R, Ma J,Zou Z,et al. Cancer statistics,2014[J]. CA Cancer J Clin,2014,64(1):9-29.
|
| [2] |
Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2010 [ EB/OL]. [ 2014-03-01 ].http:/ /seer.cancer.gov/csr/1975_2010/.
|
| [3] |
Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement[J].JAMA,2013,310(8):797-798.
|
| [4] |
Bleyer A, Welch HG. Effect of screening mammography on breast cancer incidence[J]. N Engl J Med, 2013, 368(7):679.
|
| [5] |
Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer[J]. JAMA,2009,302(15):1685-1692.
|
| [6] |
Kalager M, Zelen M, Langmark F, et al. Effect of screening mammography on breast-cancer mortality in Norway[J]. N Engl J Med,2010,363(13):1203-1210.
|
| [7] |
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer[J]. N Engl J Med,2005,353(17):1784-1792.
|
| [8] |
Anderson WF, Reiner AS, Matsuno RK, et al. Shifting breast cancer trends in the United States[J]. J Clin Oncol, 2007,25(25):3923-3929.
|
| [9] |
Alvarado M, Ozanne E, Esserman L. Overdiagnosis and overtreatment of breast cancer[J]. Am Soc Clin Oncol Educ Book,2012,32: e40-e45.
|
| [10] |
Drukker CA, Schmidt MK, Rutgers EJ, et al. Mammographic screening detects low-risk tumor biology breast cancers[J].Breast Cancer Res Treat,2014,144(1):103-111.
|
| [11] |
李惠, 孙怡, 王露, 等. 21 基因检测对乳腺癌预测和预后的意义[J]. 现代肿瘤医学,2013,21(10):2379-2382.
|
| [12] |
Tuttle TM, Jarosek S, Habermann EB, et al. Omission of radiation therapy after breast-conserving surgery in the United States: a population-based analysis of clinicopathologic factors[J]. Cancer,2012,118(8):2004-2013.
|
| [13] |
Soulos PR, Yu JB, Roberts KB, et al. Assessing the impact of a cooperative group trial on breast cancer care in the medicare population[J]. J Clin Oncol,2012,30(14):1601-1607.
|
| [14] |
Giordano SH. Radiotherapy in older women with low-risk breast cancer: why did practice not change? [J]. J Clin Oncol,2012,30(14):1577-1578.
|
| [15] |
Caudle AS, Hunt KK, Kuerer HM, et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG)Z0011 study: a practice-changing trial[J]. Ann Surg Oncol,2011,18(9):2407-2412.
|
| [16] |
Giuliano AE, Morrow M, Duggal S, et al. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? [J]. Clin Exp Metastasis,2012,29(7):687-692.
|
| [17] |
Rossari JR,Metzger-Filho O,Paesmans M,et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence[J]. J Oncol,2012,2012:417673.
|
| [18] |
Hawley ST, Griggs JJ, Hamilton AS, et al. Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients[J]. J Natl Cancer Inst,2009,101(19):1337-1347.
|
| [19] |
Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgery treatment decisions for breast cancer[J]. J Clin Oncol,2005,23(24):5526-5533.
|
| [20] |
Katz SJ,Morrow M. Addressing overtreatment in breast cancer:the doctors’ dilemma [J]. Cancer,2013,119(20):3584-3588.
|
| [21] |
Sweeney KJ, Ryan E, Canney M, et al. Justifying adjuvant chemotherapy in breast cancer: a survey of women and healthcare professionals[J]. Eur J Surg Oncol,2007,33(7):838-842.
|
| [22] |
泰洪真, 李席如. 关于乳腺癌过度治疗问题的思考[J]. 医学与社会,2009,22(2):16-18.
|
| [23] |
Nichols HB, Berrington de González A, Lacey JV Jr, et al.Declining incidence of contralateral breast cancer in the United States from 1975 to 2006[J]. J Clin Oncol, 2011, 29(12):1564-1569.
|
| [24] |
Agarwal S, Pappas L, Neumayer L, et al. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer[J]. JAMA Surg,2014,149(3):267-274.
|
| [25] |
张保宁, 张斌, 唐中华, 等. 中国乳腺癌手术治疗10 年的发展与变迁[J]. 中华肿瘤杂志,2012,34(8):582-587.
|
| [26] |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases ( IBCSG 23-01): a phase 3 randomised controlled trial [J]. Lancet Oncol,2013,14(4):297-305.
|
| [27] |
Masood S. Is it time to retire the term of “in situ carcinoma”and use the term of “borderline breast disease?” [J]. Breast J,2010,16(6):571-572.
|
| [28] |
Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast[J].Am J Surg,2003,186(4):337-343.
|
| [29] |
Cuadros M, Llanos A. Validation and clinical application of MammaPrint® in patients with breast cancer [J]. Med Clin(Barc),2010,136(14):627-632.
|
| [30] |
Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone[J]. Ann Oncol,2014,25(2):339-345.
|
| [31] |
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med,2004,351(27):2817-2826.
|
| [32] |
Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer:results from NSABP B-14 and NSABP B-20[J]. J Clin Oncol,2010,28(10):1677-1683.
|
| [33] |
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer[J]. J Clin Oncol, 2006, 24(23):3726-3734.
|
| [34] |
Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptorpositive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J]. Lancet Oncol,2010,11(1):55-65.
|
| [35] |
National Comprehensive Cancer Network. NCCN Guidelines for Senior Adult Oncology v1.2010[EB/OL]. [2014-03-02].http:/ /www. nccn. org/professionals/physician _ gls/pdf/senior.pdf.
|
| [36] |
Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial[J]. Future Oncol,2008,4(5):603-610.
|